GILUPI will participate at the 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. The meeting will take place from 4th to 7th December with more than 7.000 participants expected.
Liquid biopsy - isolating and analyzing circulating tumor cells (CTCs) from the blood of cancer patients - can provide additional information on prognosis of patients, treatment efficacy, resistance and molecular tumor evolution. Dr. Julia Herrmann, clinician at the SRH Wald-Klinikum Gera - a certified lung cancer center (DKG), will present first data from a clinical trial using the GILUPI CellCollector®, to monitor CTC counts before and after surgery in non-small cell lung cancer (NSCLC) patients. The CTCs were further characterized on a molecular level. First results from 20 patients show that CTCs were isolated independent from tumor stages and could even be detected in quite early cases. Moreover, the difference between CTC occurrence before and after surgery suggested the possibility to identify patients responding to therapy or patients with stable disease.
The poster presentation will take place on Monday the 5th December in Hall B between 2.30 pm and 3.45 pm (abstract ID 5975). You are invited to meet Dr. Julia Herrmann as well as Dr. Jens Pfannkuche (CEO, GILUPI GmbH) and Dr. Julia Schulz (GILUPI, R&D division), which will also participate at this poster session.
Liquid biopsy - isolating and analyzing circulating tumor cells (CTCs) from the blood of cancer patients - can provide additional information on prognosis of patients, treatment efficacy, resistance and molecular tumor evolution. Dr. Julia Herrmann, clinician at the SRH Wald-Klinikum Gera - a certified lung cancer center (DKG), will present first data from a clinical trial using the GILUPI CellCollector®, to monitor CTC counts before and after surgery in non-small cell lung cancer (NSCLC) patients. The CTCs were further characterized on a molecular level. First results from 20 patients show that CTCs were isolated independent from tumor stages and could even be detected in quite early cases. Moreover, the difference between CTC occurrence before and after surgery suggested the possibility to identify patients responding to therapy or patients with stable disease.
The poster presentation will take place on Monday the 5th December in Hall B between 2.30 pm and 3.45 pm (abstract ID 5975). You are invited to meet Dr. Julia Herrmann as well as Dr. Jens Pfannkuche (CEO, GILUPI GmbH) and Dr. Julia Schulz (GILUPI, R&D division), which will also participate at this poster session.
